The Future Of Nano Technology
- Alan Watts
- Anti-Aging Medicine
- David Sinclair
- Gene Medicine
- Gene therapy
- Genetic Medicine
- Genetic Therapy
- Global News Feed
- Hormone Replacement Therapy
- Human Genetic Engineering
- Human Reproduction
- Integrative Medicine
- Life Skills
- Longevity Medicine
- Machine Learning
- Medical School
- Nano Medicine
- Parkinson's disease
- Quantum Computing
- Regenerative Medicine
- Stem Cell Therapy
- Stem Cells
- Want to look better on your next Zoom call? Skin spa helps make sense of all the options out there – KPRC Click2Houston
- Two Pitt Faculty Members Inducted into National Academy of Medicine for Work on Aging and Neuro-Rehab – Newswise
- Franz Skincare USA Announces Second Consecutive Win of "Top Skincare Face Mask" in the 2020 Aesthetic Everything Aesthetic and Cosmetic…
- Dr. Kathryn Alcarez Joins The Exclusive Haute Beauty Network Representing The Medspa Category – PR Web
- Senior Horses and Living the Good Life The Horse – TheHorse.com
- Grab Pay Philippines
- GrabPay Philippines
- GrabPay Vietnam
- rajiv joshi ibm
- AI Trained on the Bible Spits Out Bleak Religious Prophecies
- hope frozem
- benchtop bioreactor market
- world economic forum how chemical industry boost stimulus
- are mushrooms the future of well ess
- Fururism this x ray map of the entire sky is
|Search Immortality Topics:|
Category Archives: Genetic Medicine
The National Academy of Medicine today announced that five members of the CUIMC facultySonia Yris Angell, Andrea Baccarelli, Wendy Chung, Kam W. Leong, and Patricia Stonehave been elected to the academy.
Members of NAM, formerly known as the Institute of Medicine, are elected by their peers in recognition of outstanding achievement. Membership is one of the highest honors bestowed in the field of medicine. The election reflects the high esteem of peers and colleagues. NAM members are part of a group of distinguished individuals who have made important contributions to health, medicine, and science.
Since 1970, when the Institute of Medicine was established as part of the congressionally chartered National Academy of Sciences, the organization's work and recommendations have shaped health research, practice, and policies that improve the lives of millions of people around the world.
The five new CUIMC members:
Sonia Yris Angell, MD, MPH, assistant clinical professor of medicine in theVagelos College of Physicians and Surgeons, was selected for her leadership in the nations first municipal regulation to ban transfat, launching national coalitions to reduce sodium and sugar in our food supply, working globally to improve control of hypertension, and for global leadership in modeling environmental change to sustainably reduce risk and save lives.
As a public health expert, Angell works on policies and programs that make places where we live, work, and play, healthier for all of us.She was previously deputy commissioner at New York City'sDepartment of Health and Mental Hygiene, overseeing the Division of Prevention and Primary Care, and was the founder and director of its Cardiovascular Disease Program. She also was a senior adviser for global noncommunicable diseases at the Centers for Disease Control and Prevention (CDC).
Andrea Baccarelli, MD, PhD, the Leon Hess Professor and Chair of the Department of Environmental Health Sciences in the Mailman School of Public Health, was selected for his pioneering work showing that environmental chemicals and lifestyle risk factors adversely affect the human epigenome, thereby producing adverse lifetime health consequences.
Baccarelli also serves as director of the Laboratory of Precision Environmental Health. An epigeneticist andclinical endocrinologist, Baccarelli helped develop powerful new tools in environmental epigenetics, not only to document the health risks of a variety of synthetic toxins, but also as an avenue to preventionand even targeted therapies. His lab has produced numerous publications at the intersection of epigenetics, molecular epidemiology, and environmental health.Over the course of his career, Baccarelli has expanded the vocabulary of epigenetics, showing how environmental damage inscribes itself in the body.
Wendy Chung, MD, PhD, the Kennedy Family Professor of Pediatrics and Medicine in theVagelos College of Physicians and Surgeons and leader of the Precision Medicine Resource in the Irving Institute, was selected for identifying the genetic basis for over 45 monogenic conditions (two of which bear her name) across a wide range of diseases and leading the pivotal study of newborn screening for spinal muscular atrophy.
Chung was the original plaintiff in the Supreme Court case that overturned the ability to patent genes and served on the Institute of Medicine's Committee on Genetic Testing. She is a board-certified clinical and molecular geneticist with 20 years of experience in human genetic research of monogenic and complex traits including diseases such as breast cancer, pancreatic cancer, congenital heart disease, pulmonary hypertension, inherited arrhythmias, cardiomyopathies, obesity, diabetes, congenital diaphragmatic hernias, and autism.
She has received the American Academy of Pediatrics Young Investigator Award, the Medical Achievement Award from Bonei Olam, the New York Academy Medal for Distinguished Contributions in Biomedical Science, and the Rare Impact Award from the National Organization of Rare Disorders. Chung is renowned for her teaching and mentoring and received Columbia University's highest teaching award, the Presidential Award for Outstanding Teaching.
Kam W. Leong, PhD, the Samuel Y. Sheng Professor ofBiomedical Engineering in the Fu Foundation School of Engineering and Applied Science (in Systems Biology in the Vagelos College of Physicians and Surgeons), was selected for his innovative developments in multifunctional nanoscale technologies for delivering drugs, antigens, proteins, siRNA, and DNA to cells.
Innovations in the Leong Lab focus on the design of therapeutic biomaterials for gene editing, drug and gene delivery, and regenerative medicine. He is developing nanocarriers that can deliver gene-editing elements to the liver for metabolic disorders, and studying the gene-editing efficiency in other tissues such as the brain and the gastrointestinal tract. Heis also working on the construction of human tissue-on-chips for disease modeling and drug development, particularly in using tissue-engineered blood vessel to model Marfan Syndrome and atherosclerosis, and generating patient-specific brain organoids to model neuropsychiatric disorders and opioid usage disorder.
Leong is internationally recognized as a leader in the development of nanoscale therapeutics. In 2013 he was elected to the National Academy of Engineering and theNational Academy of Inventors.
Patricia Stone, PhD, RN, the Centennial Professor of Health Policy and director of the Center for Health Policy in theSchool of Nursing, was selected for her expertise and sustained scholarly efforts in real-world comparative and economic evaluations of improving the quality of care and specifically preventing health care-associated infections.
Stone is dedicated to educating nurses in health policy methods as well as developing and disseminating knowledge that informs policymakers at the local, state, and national levels. She has a long history of research and has been the principal investigator on many federal and foundation-supported grants. She has served on a number of important policymaking committees, co-chaired two National Quality Forum Technical Advisory Panels, and served as an expert for the Massachusetts Expert Panel on Healthcare-Associated Infections and theCalifornia Health Department.
Her work on the cost of health care-associated infections hasbeen cited in major publications, Centers for Disease Control and Prevention guidelines, and the Health and Human Services Healthcare-Associated Infections Action Planand hascontributed to recent changes in health policy.
Mount Sinai Doctors Elected to National Academy of Medicine for Contributions to Emergency Medicine and Translational Genetics – Newswise
Newswise (New York, NY October 19, 2020) Brendan G. Carr, MD, MA, MS, Chair of Emergency Medicine for the Icahn School of Medicine at Mount Sinai and the Mount Sinai Health System, and Judy H. Cho, MD, Dean of Translational Genetics at the Icahn School of Medicine at Mount Sinai and Director of The Charles Bronfman Institute for Personalized Medicine, have been elected to the National Academy of Medicine (NAM). Election to the NAM is considered one of the highest honors in health and medicine, recognizing individuals who have demonstrated outstanding professional achievement and commitment to service. With their election, Mount Sinai has 25 faculty members in the NAM.
The recognitions of Dr. Carr and Dr. Cho are well deserved for their groundbreaking contributions to emergency medicine and translational genetics, says Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai. Dr. Carrs research has focused not only on improving the emergency care system for time-sensitive conditions such as trauma, stroke, cardiac arrest, and sepsis, but also on creating a more distributed and innovative approach to increasing access to acute care. Likewise, Dr. Cho is committed to improving care through personalized medicine and the understanding of each patients unique genes. She has enhanced genetic research, clinical implementation, and data platforms to ensure Mount Sinai remains at the forefront of genetic discoveries and implementation.
Emergency Medicine A leading voice in emergency medicine, Dr. Carr played a central role in coordinating Mount Sinais response to the COVID-19 pandemic. He has dedicated his career as an emergency medicine physician and health policy researcher to seamlessly combining research, policy, and practice to advance acute care delivery. Before joining Mount Sinai in February 2020, Dr. Carr held faculty positions at the Sidney Kimmel Medical College at Thomas Jefferson University and the Perelman School of Medicine at the University of Pennsylvania.
Outside academia, Dr. Carr has worked within the U.S. Department of Health and Human Services during both the current and previous administrations to improve trauma and emergency care services at the national level. His roles have included Senior Advisor and Director of the Emergency Care Coordination Center within the Office of the Assistant Secretary for Preparedness and Response, focusing on integrating the emergency care system into the broader health care delivery system. He previously supported the Indian Health Services initiatives to improve emergency care delivery, and worked with the Department of Veterans Affairs and the Department of Defense to integrate military and civilian health care response during disasters and public health emergencies. Dr. Carr has advised and supported major not-for-profit foundations, the World Health Organization, and the National Academy of Medicine.
He conducts health services research that connects disciplines including epidemiology, health care policy, business, economics, and health care delivery system science. His work has been continuously funded by the National Institutes of Health, the Centers for Disease Control and Prevention, and the Agency for Healthcare Research and Quality. He has published and lectured widely on systems of care for trauma, stroke, cardiac arrest, and sepsis.
Ive spent my career focused on improving access to high-quality emergency care and am extremely humbled to be recognized by my peers with this honor. The recent COVID-19 surge reminded us of the importance of building robust systems that meet the needs of the communities that we serve. Im incredibly grateful for the opportunities Ive been given and the mentors that have helped to guide my career, says Dr. Carr. I am particularly grateful to be honored alongside my Mount Sinai colleague.
Translational Genetics Dr. Cho is an internationally recognized expert on the genetics and genomics of inflammatory bowel disease. As Dean of Translational Genetics, she leads strategic planning and integration of translational genetics research and care across school departments and institutes, with a focus on the rapid application of genetic and genomic discoveries to improve patient care. She also holds the Ward-Coleman Chair in Translational Genetics as well as professorships in Genetics and Genomic Sciences, and Medicine.
In 2013, Dr. Cho joined the Icahn School of Medicine faculty following appointments at the Yale University School of Medicine and the University of Chicago Pritzker School of Medicine. For the past five years, she has been Director of The Charles Bronfman Institute for Personalized Medicine and overseen the BioMe Biobank program, a pioneer in the movement toward diagnosis and classification of disease according to the patients molecular profile.
Science generally, and genetics especially, is a team sport; this recognition reflects many, many close collaborations over the years, says Dr. Cho. It is a privilege to try to advance science to help patients, and genetic discovery provides a particularly powerful means of prioritizing novel therapeutic targets.
Dr. Cho also leads an independent research program that is generously funded by the National Institutes of Health (NIH) and other extramural sources, and chairs the External Advisory Committee of the Wellcome Trust Centers for Human Genetics and Cellular Genetics. She has been Principal Investigator of the Data Coordinating Center for the Inflammatory Bowel Disease Genetics Consortium of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) since 2002 and chaired its Steering Committee for 16 years. Previously, she served on the American Society for Clinical Investigation Council and the NIDDK External Advisory Council, and chaired the Genetics of Health and Disease Study Section at the NIH. In 2014, Dr. Cho received the Crohns and Colitis Foundations Lifetime Achievement Award in Basic Science.
New members are elected to the NAM by current, active members through a selective process that recognizes leaders making major contributions to the advancement of the medical sciences, health care, and public health. Established in 1970 by the National Academy of Sciences, NAM is a national resource that provides independent, objective analysis and advice on health issues.
The elections of Dr. Carr and Dr. Cho bring Mount Sinais total membership in the prestigious group to 25 current and emeritus faculty members: Joseph D. Buxbaum, PhD Neil S. Calman, MD, MMS Dennis S. Charney, MD Kenneth L. Davis, MD Robert J. Desnick, MD, PhD Angela Diaz, MD, MPH Valentin Fuster, MD, PhD Bruce Gelb, MD Alison M. Goate, DPhil Kurt Hirschhorn, MD Yasmin L. Hurd, PhD Philip J. Landrigan, MD, MSc Helen S. Mayberg, MD Diane E. Meier, MD Eric J. Nestler, MD, PhD Maria Iandolo New, MD Peter Palese, PhD Ramon E. Parsons, MD, PhD Lynne D. Richardson, MD Hugh A. Sampson, MD Albert Siu, MD, MSPH Barbara G. Vickrey, MD, MPH Rachel Yehuda, PhD.
About the Mount Sinai Health System
The Mount Sinai Health System is New York Citys largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality carefrom prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's Honor Roll of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in the country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty by U.S. News & World Report.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.
Stanford Medicine social scientist Meghan Halley, PhD, has learned to embrace uncertainty when making medical decisions for her 5-year-old son, Philip, who has an undiagnosed genetic disorder with physical and medical complications that never end.
"People often say to me, 'I don't know how you do it. I could never do it,' But as a parent you do it," Halley told me in a 1:2:1 podcast. "You do what you need to do."
To be sure, caring for Philip is a family affair. Her husband, she said, is "a wonderful partner ... an incredible father and advocate." An identical twin physician sister helps her understand the challenges that doctors face in treating patients with complex illnesses. And a younger sister donated a portion of her liver to Philip when he needed a transplant.
In a poignant perspective piece published last week in the New England Journal of Medicine, Halley, a researcher at the Stanford Center for Biomedical Ethics, talks about how she navigates the sea of uncertainty about Philip's care by focusing on the quality of her young son's life.
This Q&A is edited and condensed from that conversation.
When did you first learn that Philip had major medical issues?
We knew something was concerning before Philip was born. An ultrasound late in my pregnancy showed issues with his bowel, but we didn't quite know what they were.
He was born about three weeks early in an urgent induction and was rushed to the neonatal intensive care unit to be assessed. Three days later, he had a major exploratory bowel surgery that fixed a number of blockages and a large perforation.
We brought him home three weeks later, on Christmas Day -- his original due date -- feeling like we had really dodged a bullet. By New Year's, he was back in the hospital.
As the years went on, his medical condition didn't stabilize, did it?
Coming up on his third birthday, Philip woke up one morning unable to walk, speak or eat. He had a major stroke that immobilized most of the right side of his body. That was when we really started to understand the complexity of what was going on with him, and how little we knew about it.
We were referred to the National Institutes of Health's Undiagnosed Diseases Network. It's a network of geneticists and clinicians who are committed to finding answers for patients who, despite extensive clinical and genetic workups, remain without a unifying diagnosis to explain their complex health issues.
You're a social scientist in the field of biomedical research. What is the upside of being armed with data, expertise and knowledge?
As a medical anthropologist, a lot of my work and research have focused on medical decision-making: How do we support patients and families in making decisions about their health in collaboration with their physicians?
Medical decision-making is really challenging for patients and for providers even when the decisions are relatively straightforward or when there's a preponderance of medical evidence to support and inform a decision.
We've barely begun to scratch the surface of what we need to do to support patients and physicians struggling with decisions under extreme uncertainty.
What made you want to write the poignant perspective piece for the New England Journal of Medicine about Philip and your family?
I hope it reaches other patients and families grappling with undiagnosed and rare diseases, but also those facing known chronic illnesses that require repeated hospitalizations or procedures.
The experience of trying to make individual decisions, while also seeing the cumulative impact of those decisions on your family, is one that will be familiar to them.
My goal was to convey to physicians that it's OK to acknowledge and discuss uncertainty, and that couching decisions in a broader discussion of what feels feasible and right for a family can be the best medical care you can provide.
I have come to recognize that the repeated interactions with the health care system -- the chasing, with good reason, of an answer and attempts to mitigate symptoms for which there is no known cause -- has a dramatic long-term impact on Philip's and on our family's quality of life.
Is Philip's illness still an undiagnosed genetic disorder?
He has some sub-diagnoses and a conglomeration of symptoms but they have still not found a diagnosis. We remain hopeful.
Rare and undiagnosed diseases are often thought of as uncommon, but in total they actually affect about 30 million people in the United States. Individuals diagnosed with rare diseases go through a diagnostic odyssey that averages about six years.
They are trying to make the best decisions they can for their health without knowing what they are trying to fight against.
How is Philip doing today?
He has always been a happy kid -- he has the best laugh. His life is both beautifully typical and incredibly atypical.
We hope for the best, but are constantly planning for the worst. There's uncertainty in his medical condition, and that inserts a stunning level of uncertainty into his life and into our life as a family.
It's small decisions you have to make day-in and day-out that really take a toll. Do I wake Philip up to give him his medications, or does he need his sleep more than he needs a medication on time? When a provider recommends a new treatment regimen, how much do I push back because it will be too onerous for Philip?
I feel like I've had to develop my own approach and style as I've evolved as a decision-maker for Philip.
Photos courtesy of Meghan Halley. Top photo: Georgi Dakovski, Meghan Halley, and children Philip (age 5), Gabriella (age 6), and Emily (age 2).
The Office of Research and the School of Medicine had planned to introduce their Oct. 30 speaking guest as a professor and the founder and director of the Innovative Genomics Institute at UC Berkeley, and a CRISPR pioneer.
Since being booked for the Distinguished Speaker Series in Research and Innovation, however, Jennifer Doudna has added a new title: Nobel laureate.
She and Emmanuelle Charpentier, director of the Max Planck Institute for Infection Biology, won the Nobel Prize in chemistry Oct. 7 for their co-development of CRISPR-Cas9, a genome editing tool that has revolutionized biomedicine and agriculture.
Whats CRISPR? Jennifer Doudna explains in a Radiolab podcast.
Doudna became the first woman on the UC Berkeley faculty to win a Nobel, and she and Charpentier are the first women to share a Nobel in the sciences.
Doudnas topic for her UC Davis talk is CRISPR and Coronavirus.
UC Davis Healths Ralph Green, distinguished professor in the Department of Pathology and Laboratory Medicine, and medical director of UC Davis Diagnostics, recently collaborated with Doudna and others on a project to set up COVID-19 testing for UC Berkeley and the surrounding community and Green is helping with a similar project at UC Davis.
I had the good fortune to get to know Jennifer Doudna through my interaction with her group when they turned their skills and knowledge to setting up, at remarkable speed, a pop-up, PCR-based test for SARS-CoV-2 during the early days of the COVID-19 pandemic when the country was scrambling to meet the need for more testing, Green said.
I have to say that it has been a singular pleasure and privilege for me to interact with Jennifer Doudna and her colleagues.
CRISPR-Cas9 genetic engineering technology enables scientists to change or remove genes quickly and with great precision. Labs worldwide have redirected their research programs to incorporate this new tool, creating a CRISPR revolution with huge implications across biology and medicine.
Doudna is a leader in public discussion of the ethical implications of genome editing for human biology and societies. She advocates for thoughtful approaches to the development of policies around the use of CRISPR-Cas9.
Follow Dateline UC Davis on Twitter.
CooperSurgical and NYU Langone Fertility Center Announce Study Data Showing Significant Increase in Ongoing Pregnancy and Live Birth Rates with…
Data from NYU Langone Fertility Center Study Presented atAmerican Society of Reproductive Medicine Annual Meeting
TRUMBULL, Conn. and NEW YORK, Oct. 19, 2020 (GLOBE NEWSWIRE) -- CooperSurgical and NYU Langone Fertility Center (NYULFC), part of The Prelude Network, announced today independent study results demonstrating increased ongoing pregnancy and live birth rates associated with the use of CooperSurgical's PGTai 2.0 technology to screen embryos for in vitro fertilization (IVF).1 This single-center study was conducted by NYULFC; and results were presented today at the American Society of Reproductive Medicine (ASRM) Virtual Scientific Congress.
Preimplantation Genetic Testing for aneuploidy (PGT-A) is performed on embryos produced through IVF; it provides genetic information to help identify embryos that are more likely to result in a successful pregnancy. PGTai 2.0 is an advancement in PGT-A testing that utilizes artificial intelligence to increase objectivity of this screening process.
This research moves us an important step closer to our goal of increased live births, improved pregnancy outcomes and further reduction of multiples in pregnancy through greater confidence in single embryo transfer, said James A. Grifo, M.D., Ph.D., Director, NYU Langone Fertility Center.
An estimated 48.5 million couples approximately 15% of couples -- are affected by infertility worldwide.2 80,000 babies were born with IVF in 2017 in the United States3 and more than one million babies were born in the period 1987 to 2015 in the United States as a result of IVF.4
The study is a demonstration of CooperSurgicals commitment to developing the most advanced technology in the field of genetic testing to advance reproductive medicine and help families, said Tony Gordon, Vice President of Business Development, CooperGenomics. By applying artificial intelligence in the PGTaism2.0 technology, we leverage mathematical algorithms derived from real-world data to achieve objective embryo assessment.
About the Study The retrospective study included data from more than 700 patients in the NYU Langone Fertility Center in New York, N.Y.
The study compared results from three next generation sequencing (NGS) genetic tests: Standard NGS, NGS with first generation artificial intelligence (PGTai 1.0 Technology Platform) and NGS with second generation artificial intelligence (PGTai 2.0 Technology Platform). The ongoing pregnancy and live birth rates significantly increased by a relative 13 percent in the PGTai 2.0 group as compared to subjective and prior methodologies.
Study results also suggest that the increase in ongoing pregnancy and live births may be linked to improvements in several preceding IVF outcomes (implantation rates, clinical pregnancy rates and pregnancy loss).
About NYU Langone Fertility CenterNYU Langone Fertility Centerprovides world class science and exceptional clinical care to patients seeking fertility treatment. For over 25 years, the Fertility Center has been on a mission to help educate women and men about their reproductive health, and to deliver data-driven guidance at each step in the fertility care process. NYU Langone Fertility Center is proud to serve all families with compassionate, individualized, and cost-effective treatment options.
The Fertility Center has helped thousands of patients realize their dreams of having a family, and its dedicated physicians have over 125 years of collective experience performing IVF. Each physician is certified in Reproductive Endocrinology and Infertility (REI) with the American Board of Obstetrics and Gynecology, and many of its physicians also hold Professor or Assistant Professor positions within the Department of Obstetrics and Gynecology at NYU Langone Health. While they are physicians first and foremost, the Fertility Centers physicians are also active participants in clinical research to advance the safety, success, and affordability of fertility care.
About CooperSurgical CooperSurgical is a leader in delivering innovative assisted reproductive technology and genomic solutions that enhance the work of ART professionals to the benefit of families. Its experience working with embryologists and IVF professionals across the globe, and offering a portfolio of products for the entire ART process, means that it can help meet the exacting needs of ART clinics.
CooperSurgical is a wholly-owned subsidiary of CooperCompanies (NYSE: COO). CooperSurgical headquartered in Trumbull, CT, produces and markets a wide array of products and services for use by womens health care clinicians. More information can be found at fertility.coopersurgical.com.
About CooperCompaniesCooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, CA, Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit http://www.coopercos.com.
CooperSurgicalCaren BegunGreen Room Communications201email@example.com
NYU Langone Fertility CenterMia HumphreysKrupp Kommunications239-297-6592Mhumphreys@kruppnyc.com
________________________________1 Buldo-Licciardi J, Large M, McCulloh D, McCaffrey C, Grifo J. Second generation artificial intelligence technology for preimplantation genetic testing (PRT) improves pregnancy outcomes in single thawed euploid embryo transfer cycles (STEET). Presented at American Society for Reproductive Medicine on October 19, 2020. Available at: https://asrm.confex.com/asrm/2020/meetingapp.cgi/Paper/8645. Accessed October 13, 2020.2 Agarwal A, Mulgund A, Hamada A, Chyatte MR. A unique view on male infertility around the globe. Reprod Biol Endocrinol. 2015;13:37. Published 2015 Apr 26. doi:10.1186/s12958-015-0032-1. Accessed October 13, 2020. 3 Centers for Disease Control and Prevention. ART Success Rates. Available at: https://www.cdc.gov/art/artdata/index.html. Accessed October 13, 2020.4 Centers for Disease Control and Prevention, American Society for Reproductive Medicine, Society for Assisted Reproductive Technology. 2015 Assisted Reproductive Technology National Summary Report. Available at: https://www.cdc.gov/art/pdf/2015-report/ART-2015-National-Summary-Report.pdf. Accessed October 13, 2020.
Five Indian American researchers and one Bangladeshi-American have been named among the 2020 Directors New Innovator Award recipients by the National Institutes of Health.
Among the recipients are Anindita Basu, Subhamoy Dasgupta, Deeptankar DeMazumder, Siddhartha Jaiswal, Shruti Naik, and Mekhail Anwar, according to the NIH website.
Basu, of the University of Chicago, was selected for the project, Profiling Transcriptional Heterogeneity in Microbial Cells at Single Cell Resolution and High-Throughput Using Droplet Microfluidics.
The Indian American is an assistant professor in genetic medicine at the University of Chicago and leads a multi-disciplinary research group that uses genomics, microfluidics, imaging and nano/bio-materials to develop new tools to aid in diagnosis and treatment of disease.
Basu obtained a B.S. in physics and computer engineering at the University of Arkansas, Ph.D. in soft matter physics at University of Pennsylvania, followed by post-doctoral studies in applied physics, molecular biology and bioinformatics at Harvard University and Broad Institute.
Her lab applies high-throughput single-cell and single-nucleus RNA-seq to map cell types and their function in different organs and organisms, using Drop-seq and DroNc-seq that Basu co-invented during her post-doctoral work.
Dasgupta is with the Roswell Park Comprehensive Cancer Center and was named for his project, Decoding the Nuclear Metabolic Processes Regulating Gene Transcription.
Dasgupta is an assistant professor in the Department of Cell Stress Biology at Roswell Park Comprehensive Cancer Center. He earned his B.S. from Bangalore University and M.S. in biochemistry from Banaras Hindu University, India before receiving his Ph.D. in biomedical sciences from University of North Texas Health Science Center at Fort Worth, where, as a Department of Defense predoctoral fellow, he characterized the functions of a novel gene MIEN1 in tumor progression and metastasis.
He then joined the laboratory of Bert W. O'Malley, M.D. at Baylor College of Medicine, where he studied the functions of transcriptional coregulators in tumor cell adaptation and survival, as a Susan G. Komen postdoctoral fellow.
DeMazumder, of the University of Cincinnati College of Medicine, was chosen for the project, Eavesdropping on Heart-Brain Conversations During Sleep for Early Detection and Prevention of Fatal Cardiovascular Disease.
DeMazumder joined the University of Cincinnati in 2017 as assistant professor of medicine, director of the Artificial Intelligence Center of Excellence and a Clinical Cardiac Electrophysiologist after completing his doctorate at SUNY Stony Brook in Synaptic Electrophysiology, a medical degree at Medical College of Virginia-Virginia Commonwealth University, internship at Mount Sinai and residency at University of Virginia in Internal Medicine, and clinical and research fellowships at Johns Hopkins University.
His longstanding goals are to transform clinical observations into testable research hypotheses, translate basic research findings into medical advances, and evaluate personalized treatment protocols in rigorous clinical trials, while caring for patients with heart rhythm disorders and improving their quality of life.
Jaiswal, of Stanford University, was named for his project, Clonal Hematopoiesis in Human Aging and Disease.
Jaiswal is an investigator at Stanford University in the Department of Pathology, where his lab focuses on understanding the biology of the aging hematopoietic system.
As a post-doctoral fellow, he identified a common, pre-malignant state for blood cancers by reanalysis of large sequencing datasets.
This condition, termed "clonal hematopoiesis, is characterized by the presence of stem cell clones harboring certain somatic mutations, primarily in genes involved in epigenetic regulation of hematopoiesis.
Clonal hematopoiesis is prevalent in the aging population and increases the risk of not only blood cancer, but also cardiovascular disease and overall mortality. Understanding the biology of these mutations and how they contribute to the development of cancer and other age-related diseases is the current focus of work in the lab.
Naik, of New York University School of Medicine, was named for her project, Decoding Microbe-Epithelial Stem Cell Interactions in Health and Disease.
Naik is an assistant professor at New York University School of Medicine. She received her doctorate in Immunology from the University of Pennsylvania-National Institutes of Health Graduate Partnership Program.
There she discovered that normal bacteria living on our skin, known as the commensal microbiota, educate the immune system and help protect us from harmful pathogens.
As a Damon Runyon Fellow at the Rockefeller University, Naik found that epithelial stem cells can harbor a memory of inflammation which boosts their regenerative abilities and established a new paradigm in inflammatory memory, her bio states.
The Naik lab studies the dynamic interactions between immune cells, epithelial stem cells, and microbes with a focus on 3 major areas of research: Tissue regeneration and cancer, host-microbe interactions, and early in life immunity.
Anwar, of U.C. San Francisco, was named for his project, Implantable Nanophotonic Sensors forIn VivoImmunoresponse.
Anwar, whose father is from Bangladesh, is a physician-scientist at UCSF, where he is an associate professor in the Department of Radiation Oncology. Driven by the challenges his patients face when fighting cancer specifically addressing the vast heterogeneity in treatment response by identifying the optimal treatment to pair with each patients unique biology he leads a laboratory focused on developing integrated circuits (or computer chips) forin vivocancer sensing.
After completing his bachelors in physics at U.C. Berkeley, where he was awarded the University Medal, he received his medical degree at UCSF, and doctorate in electrical engineering and computer science from the Massachusetts Institute of Technology where his research focused on using micro-fabricated devices for biological detection.
Continue reading here:
Five Indian American Researchers Named Among NIH 2020 New Innovator Awardees - India West